The Claim
Dual blockade of GDF8 (myostatin) and activin A during GLP-1 receptor agonist treatment in obese male mice and non-human primates preserves or increases lean muscle mass while simultaneously enhancing fat mass loss, resulting in improved body composition and metabolic markers such as reduced liver fat and improved lipid profiles.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese male mice and non-human primates, blocking two specific proteins (GDF8 and activin A) while using a GLP-1 receptor agonist helps maintain or increase muscle mass and enhances fat loss, leading to better body composition and improved metabolic indicators like lower liver fat and healthier blood lipids.
See the scientific wording
Dual blockade of GDF8 (myostatin) and activin A during GLP-1 receptor agonist treatment in obese male mice and non-human primates preserves or increases lean muscle mass while simultaneously enhancing fat mass loss, resulting in improved body composition and metabolic markers such as reduced liver fat and improved lipid profiles, suggesting a potential strategy to mitigate the adverse muscle-wasting effects of appetite-suppressing obesity therapies.
What the research says
1 studyThis study found that when obese mice and monkeys were given a drug to reduce appetite (like those used in humans) plus another treatment that blocks two specific muscle-wasting signals, they kept more muscle and lost more fat — exactly what the claim says. It’s like stopping your body from breaking down muscle while it’s trying to lose weight.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.